Viewing nowCombinationCombiron Tablets 10/8 Milligrams
Rosuvastatin Calcium 10.4mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.

MFDS item code 201702402 · Approved 2017.05.16 · Insurance code 657203100
Treatment of hypertension and heart failure, suppression of dyslipidemia and atherosclerosis, and prevention of cardiovascular disease
This medication is used for patients who require the simultaneous administration of Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil is primarily used for the treatment of essential hypertension and assists patients with heart failure with reduced left ventricular function who require additional ACE inhibitor therapy or who are intolerant to this treatment. Rosuvastatin is used as an adjunctive treatment for patients with primary hyperlipidemia and mixed dyslipidemia when dietary modifications and exercise alone are insufficient for control. It is also suitable as an adjunct to diet in patients with homozygous familial hypercholesterolemia and primary dysbetalipoproteinemia. In patients with hyperlipidemia, it lowers LDL cholesterol, which delays the progression of atherosclerosis and is effective in reducing the risk of stroke, myocardial infarction, and arterio-vascular interventions in patients with specific cardiovascular risk factors. This medication improves heart health by managing both hypertension and hyperlipidemia simultaneously.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil, taken orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment options should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or longer and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and should continue it throughout the treatment period. This medicine may be taken at any time of the day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking candesartan cilexetil and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Safety and efficacy have not been established in adolescents and children 18 years of age or younger. Safety and efficacy have not been established in adolescents and children 18 years of age or younger.
This medication can cause severe harm to the fetus and newborn if taken during pregnancy, particularly in the second and third trimesters. It must be discontinued immediately if pregnancy is confirmed. It should not be used in patients with hypersensitivity to this medication, severe liver disease, severely impaired kidney function, pregnant or breastfeeding women, or patients with muscle disorders. Elderly patients or those with hyperkalemia, liver disorders, heart disease, or kidney transplant patients should use this medication with caution, and extra caution is necessary if there is a high risk of muscle pain or myopathy. During treatment with this medication, side effects such as headaches, itching, dyspepsia, and muscle pain may occur, so patients should consult with a doctor if symptoms are severe. If any muscle-related adverse symptoms occur, the patient should immediately inform the doctor and confirm muscle damage through blood tests, and may need to stop taking the medication in severe cases. This medication may interact with other antihypertensive agents, diuretics, anticoagulants, etc., so any other medications being taken should be reported. Pregnant or breastfeeding women should not use this medication, and women of childbearing potential should use appropriate contraception. This medication has not been established as safe and effective for children and is not recommended for their use. Elderly patients should take it cautiously while periodically monitoring kidney function and blood pressure. In case of overdose, symptoms such as hypotension and dizziness may occur, and appropriate treatment should be sought immediately at a medical facility. Care should be taken due to the possibility of dizziness caused by hypotension during driving or operating machinery.
Headache, nasopharyngitis, localized infections, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, indigestion, elevated blood sugar, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, headache, itching, nausea, generalized pruritus, dizziness, orthostatic dizziness, molluscum contagiosum, periodontitis, chest discomfort, inflammation, foreign body sensation, musculoskeletal pain, neck pain, cataract, elevated blood sugar, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, constipation, nausea, abdominal pain, pancreatitis, vascular edema, hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, diabetic neuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, memory decline, forgetfulness, amnesia, cognitive impairment, confusion, severe muscle weakness, ocular myasthenia, hypotension, hyperkalemia, renal function impairment, increased creatinine, increased urea, increased potassium, decreased sodium, elevated ALT, increased CK, increased blood pressure, cerebral infarction, spondyloarthritis myelopathy, musculoskeletal discomfort, pneumonia, femoral fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, productive cough, exacerbation of hypertension, unstable blood pressure, vertigo, orthostatic vertigo, adrenal insufficiency, shock, syncope, loss of consciousness, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, dry mouth, sleep disorders, decreased libido, forgetfulness, anorexia, increased appetite, tinnitus, taste disturbance, erectile dysfunction, joint pain, numbness, paresthesia, chest discomfort, abdominal pain, diarrhea, anorexia, abdominal distension, syncope, generalized pain, muscle cramps, gout
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture; therefore, it should be stored in a sealed container. It is recommended to maintain a storage temperature between 1°C and 30°C to safely preserve the medication's efficacy.
Pink round film-coated tablets
30 tablets (10 tablets/PTP X 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
AlboGen Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Candesartan Cilexetil 32mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 16mg
Tablet · Prescription medication · Combination
Alvogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Alvogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 16mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Candesartan Cilexetil 32mg
Tablet · Prescription medication · Combination
Hwanin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.